• Nintedanib (BIBF 1120) Research Workflows

  2026-09-05

  Build reproducible Nintedanib assays around receptor biology, ATRX-aware glioma stratification, and orthogonal measures of apoptosis and angiogenesis. This guide distinguishes evidence-supported starting conditions from optimization choices for cancer, fibrosis, and translational model development.

• Recombinant Annexin V for Apoptosis Detection

  2026-09-04

  Brumatti, Sheridan, and Martin describe a practical bacterial-expression and purification workflow for polyhistidine-tagged recombinant annexin V, followed by FITC conjugation for detecting phosphatidylserine exposure. The study’s main contribution is a reproducible route to a soluble probe that supports flow-cytometric and microscopic analysis of apoptotic membrane changes.

• Broad-Spectrum Bivalent mRNA Vaccine: RQ3025 Study

  2026-09-04

  Lu and colleagues evaluated RQ3025, a bivalent mRNA vaccine designed around shared SARS-CoV-2 spike mutations, in several animal models. The vaccine generated broad neutralizing activity, protected vaccinated rats against emerging variants, induced a Th1-biased cellular response, and showed no histological toxicity in the reported high-dose rat assessment.

• 5-Aminolevulinic acid HCl in Infection Research

  2026-09-03

  5-Aminolevulinic acid HCl provides a practical way to perturb heme-pathway flux while separating bacterial metabolism from host-cell effects. This article translates Salmonella phagocytosis findings into assay workflows, controls, optimization steps, and carefully bounded cancer-research applications.

• Firefly Luciferase mRNA for Causal Assay Design

  2026-09-03

  Firefly Luciferase mRNA (ARCA, 5mCTP, ΨUTP) can function as more than a transfection control: it helps researchers distinguish delivery, translation, cellular energy, and assay-specific effects. This guide develops a mechanistic workflow informed by engineered mRNA delivery research and practical reporter-assay design.

• Erastin: From Ferroptosis Mechanism to Translation

  2026-09-02

  Erastin is more than a ferroptosis inducer: it is a mechanistic probe for testing how oncogenic context, iron handling, redox balance, and system Xc⁻ vulnerability converge in tumor cells. This thought-leadership guide connects recent iron- and ROS-dependent plant defense findings with practical experimental design and translational decision-making in cancer biology research.

• GSK2606414: Selective PERK Inhibitor Guide

  2026-09-02

  GSK2606414 is a potent PERK inhibitor with a reported biochemical IC50 of 0.4 nM and strong kinase-panel selectivity. It supports controlled ER stress research and helps connect PERK–eIF2α signaling with disease-model phenotypes, while requiring careful separation of compound evidence from genetic pathway evidence.

• WIP1/PPM1D, p38 MAPK, and Pyroptosis in AKI

  2026-09-01

  The reference study identifies WIP1/PPM1D as a phosphatase that restrains p38 MAPK-associated pyroptosis in sepsis-associated acute kidney injury. By combining single-cell data, human and mouse kidney analyses, and pharmacological inhibition in HK2 cells and mice, it connects PPM1D signaling pathway activity with renal tubular inflammatory cell death.

• (-)-Blebbistatin in Multimodal Cardiac Research

  2026-09-01

  A strategic framework for using (-)-Blebbistatin as a reversible non-muscle myosin II perturbation alongside transparent, stretchable cardiac bioelectronics. The approach links cytoskeletal mechanics with electrophysiology, metabolism, and translational disease modeling without confusing measurement with mechanism.

• HyperScribe All in One mRNA Synthesis Kit Guide

  2026-08-31

  Build translation-ready, ARCA-capped and polyadenylated transcripts through one coordinated workflow for vaccine, translation, antisense, and RNAi studies. This practical guide connects bench-scale RNA quality control with the spleen-targeted neoantigen vaccine findings reported in hepatocellular carcinoma research.

• CDELNs Relieve Sertoli Cell Cycle Arrest

  2026-08-31

  The reference study reports that Cistanche deserticola exosome-like nanovesicles protect against cyclophosphamide-induced testicular injury by delivering miR159b-3p to Sertoli cells. The proposed mechanism links heparan sulfate proteoglycan-mediated uptake with suppression of P21 and phosphorylation-dependent CDK1 activation, while human single-cell data provide translational context.

• Nintedanib: ATRX-Aware Angiokinase Research

  2026-08-30

  Nintedanib (BIBF 1120) is a multi-receptor kinase probe for dissecting angiogenesis, fibrosis, and genotype-dependent tumor responses. This article develops an ATRX-aware assay strategy that separates vascular effects from tumor-cell-intrinsic sensitivity.

• Reelin Signaling Enables Ketamine Synaptic Action

  2026-08-29

  The reference study identifies Reelin–Apoer2–Src family kinase signaling as a permissive system required for ketamine-induced hippocampal plasticity and behavioral responses. Its combination of genetic disruption, pharmacological pathway testing, electrophysiology, and behavioral analysis suggests that preserved baseline NMDA receptor function may help determine ketamine responsiveness.

• CGRP/SP–Piezo2 Signaling in Trigeminal Allodynia

  2026-08-28

  Liao et al. identify a Ca2+-dependent CGRP/SP–Piezo2 positive-feedback loop linking trigeminal root compression, neuroinflammation, and mechanical allodynia. Their combination of behavioral, molecular, pharmacological, and gene-silencing approaches places the TG neuron–Merkel cell axis at the center of peripheral sensitization in trigeminal neuralgia.

• Phebestin: A Bestatin-Related Antiplasmodial Inhibitor

  2026-08-28

  The reference study identifies phebestin as a nanomolar antiplasmodial compound active against both chloroquine-sensitive and chloroquine-resistant Plasmodium falciparum, with activity across parasite stages and in mouse malaria models. Its combination of phenotypic, stage-specific, washout, computational, and in vivo evidence supports aminopeptidases as a useful target class while highlighting the limits of translating early efficacy into a therapeutic candidate.

7875 records 1/525 page Next 12345 下5页 Last page